Total Funding
64
14
Total FundingSeed raised
Growth Score
-8 pts
Heat Score
-23 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
605422
Neurolixis is a biopharmaceutical company that develops drugs for the treatment of central nervous system disorders.
Mark Varney: CEO- Adrian Newman-Tancredi: Co-Founder & Chief Executive Officer
About the Company
Neurolixis is a clinical-stage specialty pharmaceutical company focused on developing medicines targeting unmet disorders of the nervous system. The Company has two therapeutic candidates in clinical development: NLX-112, a potential symptomatic treatment for Parkinson's disease (PD) dyskinesia, is ready for Phase 2 clinical trials.
